Uk authorizes regeneron antibody cocktail to prevent and treat acute covid-19 infection

Tarrytown, n.y., aug. 20, 2021 /prnewswire/ --  uk chief medical officers to confirm how antibody cocktail will be rolled-out on the national health service (nhs) in the coming weeks in the u.s., regeneron has completed the first fda bla submission for the antibody cocktail; more than 130,000 doses were distributed in the past week to address covid-19 outbreaks regeneron pharmaceuticals, inc. (nasdaq: regn) today announced that the united kingdom's (uk) medicines and healthcare products regulatory agency (mhra) has granted conditional marketing authorization (cma) for the casirivimab and imdevimab antibody cocktail, known as regen-cov™ in the u.s. and ronapreve® in the uk and other countries, to prevent and treat acute covid-19 infection.
REGN Ratings Summary
REGN Quant Ranking